Severe SepsisNCT01249222
Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasmapheresis
A study testing plasmapheresis in people with Severe Sepsis, run by Tehran University of Medical Sciences at 1 site in Iran.
Trial summary
Sepsis is one of the most prevalent and fatal diseases in intensive care units .unfortunately, therapeutic approach to sepsis has remained unchanged for many years. Nowadays, the role of cytokines in pathogenesis of sepsis is obvious. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Severe Sepsis
- What is being tested?
- plasmapheresis
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteIran
- Study dates
- Nov 2008to Feb 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Severe sepsis criteria which were defined by the ACCP/SCCM consensus conference
Who cannot join
- Post CPR, pregnant and under 16 years old patients
Trial locations and contacts
1 site in 1 country.
Iran1 site, 1 recruiting
- Recruiting
Tehran University of Medical sciences, Imam hospital
Tehran, Tehran Province, 1417653761
Mojtaba Mojtahedzadeh, Ph.D, 009821-6695-9090, Mojtahed@sina.tums.ac.ir
Hadi Hamishehkar, Pharm.D
About this study
Official title: Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasma Therapeutic Exchange
Sepsis is one of the most prevalent and fatal diseases in intensive care units .unfortunately, therapeutic approach to sepsis has remained unchanged for many years. Nowadays, the role of cytokines in pathogenesis of sepsis is obvious. Continuous elevated levels of various cytokines in severe sepsis could result in uncontrolled inflammation status. Breaking of inflammatory cascade may lead to improvement in survival. It seems that modulation of inflammation is one of the strategic plans to conquest sepsis. Therefore, elimination of bacterial toxins and pro-inflammatory cytokines from the systemic circulation by plasmapheresis supposed to be rational approach.
Researchers have done several attempts to clarify the efficacy of plasmapheresis in sepsis treatment. However because of inconsistent results, routine use of this procedure in patients with severe sepsis remains controversial.
The aim of the present survey is to determine the effect of plasmapheresis on plasma levels of main pro-inflammatory cytokines and evaluate its therapeutic efficacy in improvement of outcome and treatment of severe sepsis.
Read the detailed description
Method 27 patients with sepsis less than 24 hours, admitted in ICU, 16- 60 years old, male and female, randomized divided two groups(P=12, S=15) study in randomized clinical trial.
Inclusion criteria:
A: At least 3 of SIRS criteria;
- 36> Tem> 38 ◦c
- HR>90 bpm (without medication)
- RR>20 bpm or PaCo2≤ 32 on mechanical ventilation
- WBC<4000 or >12000 or > 10% immature neutrophil
B: Documented diagnosis of sepsis (separation organism from blood, urine, CSF, secretions such as trachea and sore) or strong suspect for infection with at least one of following:
- WBC in sterile area,
- Perforated viscera,
- Radiological evidences of pneumonia,
- High risk of infection such as cholangitis. Severity of disease is appointed with APACHE II (on result of laboratories in last 24 hours)
Exclusion criteria:
- Pass more than 24 hours from diagnosis of sepsis.
- High likelihood of mortality (renal failure, hepatic encephalopathy, ….) or imminent death(APACHE II score >25)
- Pregnant or lactescent woman
- 16 > age years old
- No satisfaction of patient
Treatments of S group include:
- Early goal - directed resuscitation
- Appropriate diagnostic studies prior to antibiotics
- Early broad - spectrum antibiotics
- Narrowing antibiotic therapy based on microbial therapy and clinical data
- Source control
- Stress dose steroids for septic shock
- Target Hb values of 7-9 g/dl in absence of coronary artery disease or acute hemorrhage
- Lung protective ventilation for ALI/ARDS
- Avoidance of Neuromuscular blockade
- Maintenance of blood glucose < 150mg/dl
- DVT/stress ulcer prophylaxis
In plasmapheresis (P) group, plasmapheresis will add into conventional therapy which is mentioned above. volume of plasmapheresis is 20-40 ml/Kg with five time in a week (distance 24-48 hours) that will do with speed of 60-120 ml/min through of central venous catheter.
Steps of plasmapheresis:
- calculation of plasma volume
- PT, PTT, Plt before and after plasmapheresis
- Replacement plasma with albumin 20% and/or normal saline
- Check of serum calcium before and after plasmapheresis. Injection of calcium gluconate 10%.
- Stop of all of drugs (except vasopressor)
- Cardiovascular monitoring during plasmapheresis
- Infusion of heparin 500 u/h Demographic characters of patients (age, sex, weight, BMI) will record. Central venous, arterial line and Foley catheter will insert. For all of patients will do follow assays daily: CVP, BP, ABG, BUN, Cr, Na, K, CBC, PLT, PT, PTT, U/A, P, Ca, Mg, Chest X Ray. LFT and Alb
Level of biomarkers evaluate at 1st, 3rd, 5th, 7th and 14th day of study. In P group, evaluation will do before and after of plasmapheresis. Biomarkers include:
- TNF-α (early release cytokine)(plasma)
- IL-1 (early release cytokine)(plasma)
- IL-6 (pro \& anti-inflammatory cytokine)(plasma) Patient will evaluate for 14 days or until death. Patient's morbidity will record until 30 days.
Evaluation of morbidity will do by scoring systems:
- TISS score (Therapeutic intervention scoring system): for evaluation of severity of care.
- SOFA score (Sepsis- related organ function assessment): for evaluation of organ function.
- ADL score (Activities of daily living) Recorded information will analyze by t- test for quantitative variables and χ 2 square for qualitative variables, with α = 0/05.
- Conditions
- Severe Sepsis
- Being tested
- plasmapheresis
- Medical subject headings
- Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
plasmapheresisProcedure or surgery
Also called plasma exchange
Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
plasmapheresisOther
Also called plasma exchange
plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
| Study group | Role | What they receive |
|---|---|---|
| conventional treatment | No intervention | Not described Receives: Other: plasmapheresis |
| Plasmapheresis | Experimental | Not described Receives: Procedure: plasmapheresis; Other: plasmapheresis |
What is being measured
The primary outcome is the main question the study is designed to answer.
mortality
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2010 (estimated)
- Study startNov 2008
- Primary completionFeb 2011 (estimated)
- Study completionFeb 2011 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Severe SepsisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tehran University of Medical Sciences
- Sponsor type
- University, hospital or other
- Investigators
- Mojtaba Mojtahedzadeh, Ph.D, Study chair, 1Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01249222
- Sponsor's protocol ID
- D-230-402
- Status last verified
- Nov 2010
- First submitted
- 22 Nov 2010
- Last updated
- 29 Nov 2010
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 29 Nov 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasma Therapeutic Exchange
- ClinicalTrials.gov ID
- NCT01249222
- Acronym / sponsor ID
- D-230-402
- Conditions
- Severe Sepsis
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 27 participants (estimated)
- Lead sponsor
- Tehran University of Medical SciencesUniversity, hospital or other
- Study start
- Nov 2008
- Primary completion
- Feb 2011 (estimated)
- Study completion
- Feb 2011 (estimated)
- First posted
- 29 Nov 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sepsis is one of the most prevalent and fatal diseases in intensive care units .unfortunately, therapeutic approach to sepsis has remained unchanged for many years. Nowadays, the role of cytokines in pathogenesis of sepsis is obvious. Continuous elevated levels of various cytokines in severe sepsis could result in uncontrolled inflammation status. Breaking of inflammatory cascade may lead to improvement in survival. It seems that modulation of inflammation is one of the strategic plans to conquest sepsis. Therefore, elimination of bacterial toxins and pro-inflammatory cytokines from the systemic circulation by plasmapheresis supposed to be rational approach.
Researchers have done several attempts to clarify the efficacy of plasmapheresis in sepsis treatment. However because of inconsistent results, routine use of this procedure in patients with severe sepsis remains controversial.
The aim of the present survey is to determine the effect of plasmapheresis on plasma levels of main pro-inflammatory cytokines and evaluate its therapeutic efficacy in improvement of outcome and treatment of severe sepsis.
Detailed description
Method 27 patients with sepsis less than 24 hours, admitted in ICU, 16- 60 years old, male and female, randomized divided two groups(P=12, S=15) study in randomized clinical trial.
Inclusion criteria:
A: At least 3 of SIRS criteria;
- 36> Tem> 38 ◦c
- HR>90 bpm (without medication)
- RR>20 bpm or PaCo2≤ 32 on mechanical ventilation
- WBC<4000 or >12000 or > 10% immature neutrophil
B: Documented diagnosis of sepsis (separation organism from blood, urine, CSF, secretions such as trachea and sore) or strong suspect for infection with at least one of following:
- WBC in sterile area,
- Perforated viscera,
- Radiological evidences of pneumonia,
- High risk of infection such as cholangitis. Severity of disease is appointed with APACHE II (on result of laboratories in last 24 hours)
Exclusion criteria:
- Pass more than 24 hours from diagnosis of sepsis.
- High likelihood of mortality (renal failure, hepatic encephalopathy, ….) or imminent death(APACHE II score >25)
- Pregnant or lactescent woman
- 16 > age years old
- No satisfaction of patient
Treatments of S group include:
- Early goal - directed resuscitation
- Appropriate diagnostic studies prior to antibiotics
- Early broad - spectrum antibiotics
- Narrowing antibiotic therapy based on microbial therapy and clinical data
- Source control
- Stress dose steroids for septic shock
- Target Hb values of 7-9 g/dl in absence of coronary artery disease or acute hemorrhage
- Lung protective ventilation for ALI/ARDS
- Avoidance of Neuromuscular blockade
- Maintenance of blood glucose < 150mg/dl
- DVT/stress ulcer prophylaxis
In plasmapheresis (P) group, plasmapheresis will add into conventional therapy which is mentioned above. volume of plasmapheresis is 20-40 ml/Kg with five time in a week (distance 24-48 hours) that will do with speed of 60-120 ml/min through of central venous catheter.
Steps of plasmapheresis:
- calculation of plasma volume
- PT, PTT, Plt before and after plasmapheresis
- Replacement plasma with albumin 20% and/or normal saline
- Check of serum calcium before and after plasmapheresis. Injection of calcium gluconate 10%.
- Stop of all of drugs (except vasopressor)
- Cardiovascular monitoring during plasmapheresis
- Infusion of heparin 500 u/h Demographic characters of patients (age, sex, weight, BMI) will record. Central venous, arterial line and Foley catheter will insert. For all of patients will do follow assays daily: CVP, BP, ABG, BUN, Cr, Na, K, CBC, PLT, PT, PTT, U/A, P, Ca, Mg, Chest X Ray. LFT and Alb
Level of biomarkers evaluate at 1st, 3rd, 5th, 7th and 14th day of study. In P group, evaluation will do before and after of plasmapheresis. Biomarkers include:
- TNF-α (early release cytokine)(plasma)
- IL-1 (early release cytokine)(plasma)
- IL-6 (pro \& anti-inflammatory cytokine)(plasma) Patient will evaluate for 14 days or until death. Patient's morbidity will record until 30 days.
Evaluation of morbidity will do by scoring systems:
- TISS score (Therapeutic intervention scoring system): for evaluation of severity of care.
- SOFA score (Sepsis- related organ function assessment): for evaluation of organ function.
- ADL score (Activities of daily living) Recorded information will analyze by t- test for quantitative variables and χ 2 square for qualitative variables, with α = 0/05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| conventional treatment | No intervention | Other: plasmapheresis |
| Plasmapheresis | Experimental | Procedure: plasmapheresis, Other: plasmapheresis |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Severe sepsis criteria which were defined by the ACCP/SCCM consensus conference
Key exclusion criteria (1 listed)
- Post CPR, pregnant and under 16 years old patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| plasmapheresisAlso: plasma exchangePlasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure. | Procedure or surgery | Plasmapheresis |
| plasmapheresisAlso: plasma exchangeplasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg. | Other | Plasmapheresis, conventional treatment |
Primary outcome
mortality
Time frame: 28 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Nov 2010.
Related trials for Severe Sepsis
RecruitingObservational study
Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn Patients
Sepsis, Sepsis-induced Coagulopathy
RecruitingObservational study
Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn Patients
Peer Bullying Intervention, Vodcast
Not yet recruitingObservational study
Blood Pressure Goal in Preterm Preeclampsia
Hypertensive Disorder of Pregnancy, Preeclampsia
Not yet recruitingEarly Phase 1
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
EBV Viremia, CMV Viremia
Recruiting
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
Septic Shock, Methylene Blue
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mojtaba Mojtahedzadeh, Ph.D study chair
1Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing plasmapheresis in people with Severe Sepsis, run by Tehran University of Medical Sciences at 1 site in Iran.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Nov 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact mojtaba mojtahedzadeh, Ph.D (009821-6695-9090, Mojtahed@sina.tums.ac.ir), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mortality (time frame: 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2010.